Guy Hermans, Ph.D.

Chief Scientific Officer at Isogenica

Speaker

Guy joined Isogenica as CSO in 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development. At Isogenica, he leads the internal technology and product development, as well as drive scientific interactions with licensees and other partners.

In his previous position as Research Fellow at Ablynx, he conceived of many of its internal drug development programs and led a number of them through preclinical development. He was also responsible for several technology development programs, addressing challenging target classes or enabling novel applications for domain antibodies.

During his academic training, Guy did research in the pathogenesis and immunotherapy of autoimmune and inflammatory disorders, ranging from cell-based immunotherapy clinical trials in Multiple Sclerosis patients (PhD, University of Hasselt) to preclinical in vitro/in vivo target discovery and validation work as postdoc at Stanford University Medical School.